Calithera Biosciences Reports Second Quarter 2017 Financial Results and Recent Highlights
Calithera Biosciences, Inc. (CALA)
Last calithera biosciences, inc. earnings: 3/11 04:10 pm
Check Earnings Report
US:NASDAQ Investor Relations:
calithera.com
Company Research
Source: GlobeNewswire
SOUTH SAN FRANCISCO, Calif., Aug. 08, 2017 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer, announced today its financial results for the second quarter ended June 30, 2017. As of June 30, 2017, cash, cash equivalents and investments totaled $208.2 million. “Recent highlights included the presentation of clinical trial results of CB-1158, a first-in-class small molecule arginase inhibitor, in an oral presentation at the American Society of Clinical Oncology, and the advancement of CB-839 into Phase 2 clinical trials in renal cell carcinoma and triple negative breast cancer,” said Susan Molineaux, PhD, President and Chief Executive Officer of Calithera. “Looking forward to the second half of 2017, we plan to present clinical updates on CB-839, including the initial results
Show less
Read more
Impact Snapshot
Event Time:
CALA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CALA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CALA alerts
High impacting Calithera Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
CALA
News
- Calithera Biosciences, Inc. (NASDAQ: CALA) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- Calithera Biosciences, Inc. (NASDAQ: CALA) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- Calithera Biosciences, Inc. (NASDAQ: CALA) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- Calithera Biosciences, Inc. (NASDAQ: CALA) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- Calithera Biosciences, Inc. (NASDAQ: CALA) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat